C-0MX7Attralus
pan-amyloid removal, biologics, amyloid imaging
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-0MX7
C-0MX7C-0MX7pan-amyloid removal, biologics, amyloid imaging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Attralus pan-amyloid removal, biologics, amyloid imaging
Attralus is developing pan-amyloid removal therapeutics intended to eliminate toxic, disease-causing amyloid in organs and tissues of patients with systemic amyloidosis. Its approach targets the underlying disease across types and stages of amyloidosis, aiming to go beyond treatments that slow progression. The site also states that its proprietary technology enabled novel biologics and the world's first amyloidosis-specific imaging agent, which was acquired by Bayer.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Attralus — Near-term readout · Bottom quartile. Derived deterministically from 9 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic